College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.
Int J Mol Sci. 2024 Sep 1;25(17):9510. doi: 10.3390/ijms25179510.
Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease that affects millions of people worldwide, and current treatment methods have certain limitations. This study aimed to explore the therapeutic potential and mechanism of action of lemairamin (Wgx-50) in inflammatory bowel disease (IBD). We used dextran sulfate sodium (DSS)-treated zebrafish as an inflammatory bowel disease model, and observed the effect of Wgx-50 on DSS-induced colitis inflammation. The results of the study showed that Wgx-50 could reduce the expression of pro-inflammatory cytokines induced by DSS and inhibit the recruitment of neutrophils to the site of intestinal injury. Further experiments revealed that Wgx-50 exerted its anti-inflammatory effect by regulating the activation of the Akt pathway. These research findings indicate that Wgx-50 possesses anti-inflammatory activity.
炎症性肠病(IBD)是一种慢性非特异性肠道炎症性疾病,影响着全球数百万人,目前的治疗方法存在一定的局限性。本研究旨在探讨 Lemairamin(Wgx-50)在炎症性肠病(IBD)中的治疗潜力和作用机制。我们使用葡聚糖硫酸钠(DSS)处理的斑马鱼作为炎症性肠病模型,观察 Wgx-50 对 DSS 诱导的结肠炎炎症的影响。研究结果表明,Wgx-50 可以降低 DSS 诱导的促炎细胞因子的表达,并抑制中性粒细胞向肠道损伤部位的募集。进一步的实验表明,Wgx-50 通过调节 Akt 通路的激活发挥其抗炎作用。这些研究结果表明,Wgx-50 具有抗炎活性。